Our Pipeline
Leading the Way in Cell Therapy
Our pipeline of cancer therapies in the areas of cell therapy, immuno-oncology, and targeted therapies includes investigational therapies and next-generation technologies that have the power to transform the way cancer is treated. As we look to the future, we remain focused on advancing technologies that could someday address additional hematological malignancies and solid tumors.
PROGRAM
PHASE
- PHASE 1
- PHASE 2
- PHASE 3
- NDA / BLA / MAA
Tecartus® (brexu-cel)1
- BLA / MAA
Yescarta® (axi-cel)2
- BLA
Yescarta® (axi-cel)
- PHASE 3
Yescarta® (axi-cel)
- PHASE 2
Yescarta® (axi-cel)3
- PHASE 2
Brexu-cel2
- PHASE 2
Brexu-cel2
- PHASE 2
Trial:
ZUMA-4
Pediatric acute lymphocytic leukemia and pediatric non-Hodgkin's lymphoma
Yescarta® (axi-cel)4
- PHASE 1
Brexu-cel
- PHASE 1
Yescarta® (axi-cel)5
- PHASE 1
KITE-718 (MAGE-A3/A6)6
- PHASE 1
KITE-439 (HPV-16 E7)6
- PHASE 1
1 Conditional approvals.
2 Breakthrough therapy designation.
3 Clinical collaboration with Genentech.
4 Clinical collaboration with Humanigen.
5 Clinical collaboration with Pfizer.
6 Collaboration with NIH.
Axi-cel - Axicabtagene ciloleucel.
Brexu-cel - Brexucabtagene autoleucel.
The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.
Some of the content on this page is not intended for users outside the US.